Divya Patel, CEO
Divya has worked with Alvogen since 2009 and formally joined the company in 2012. He was appointed as the CEO of Alvogen and its affiliate Almaject in January 2026. Divya has held various pharmaceutical leadership positions during the past 30 years, including Executive Chairman of Actavis in the US. In addition, he has more than 20 years of experience in healthcare investing with a focus on the pharmaceutical and longevity-science sectors. For Alvogen, he provides a proven track record as a senior leader in the generic pharmaceutical space.
Leadership team
Almaject is a subsidiary of Alvogen. Almaject's leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new injectable generic pharmaceutical products quickly and safely to market.